Pilot assessment of clinical and laboratory manifestations dynamics in patients with moderate coronavirus disease-19 (COVID-19) during the first week of hospitalization


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Purpose: to evaluate clinical symptoms and laboratory parameters dynamics in patients with coronavirus disease-19 during hospitalization first week. Material and methods. The prospective study included 38 patients (21 women and 17 men) with moderate coronavirus disease-19. Questioning, clinical examination and laboratory parameters estimation were carried out. The European life quality questionnaire and health visual-analog scale (VAS) were used. General blood analysis was evaluated. Patients were examined at the hospitalization moment and after 7 days. Statistical analysis was carried out with Wilcoxon and McNemar's tests in critical p-value<0.050. Data were presented as median and quartiles. Results. Patients were hospitalized on average 7 (5+10) days after the disease onset. During the observation period there was decreasing number of patients' suffering from cough (from 27 to 21; p=0,041), breath shortness (from 15 to 8; p=0,045), anosmia (from 14 to 2; p=0,001), dysgeusia (from 10 to 2; p=0,027), weakness (from 30 to 17, p=0,002), headache (from 21 to 10; p=0,022), myalgia (from 11 to 3, p=0.013), nausea (from 9 to 3; p=0,041). Health general state improved from 60 (50+75) to 80 (55+87) points (p <0,001), discomfort feeling decreased from 2 (1+2) to 1 (1+2) points (p=0,025). During the week, hemoglobin concentration decreased from 137,5 (128,0+145,0) g/l to 125,5 (119,0+136,0) g/l (p <0,001) and the platelet count increased from 217,5 (179,0+279,0) 109/ l to 295,0 (235,0+367,0) 109/l (p=0,027). Conclusion. During the first week of hospitalization, weakness, headache, myalgia, breath shortness, cough, anosmia, dysgeusia, nausea regress, the hemoglobin level decreases, the platelet count increases moderately.

Full Text

Restricted Access

About the authors

N. V Izmozherova

Ural State Medical University of the Ministry of Healthcare of Russia

Email: nadezhda_izm@mail.ru
MD, head of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

Artem A. Popov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: art_popov@mail.ru
MD, head of the Department of hospital therapy and urgent medical care service 620028, Yekaterinburg, 3 Repina Str

Andrey I. Tsvetkov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: cp-gendir@mail.ru
PhD, head of the Department of public welfare and public health 620028, Yekaterinburg, 3 Repina Str

Igor V. Borzunov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: ivborzunov@e1.ru
MD, professor of the Department of urology, nephrology and transplantology 620028, Yekaterinburg, 3 Repina Str

Alexander I. Stepanov

Central City Clinical Hospital No. 6

Email: mbucgkb6@mail.ru
Chief physician 620149, Yekaterinburg, 34 S. Deryabinoy Str

Elmira R. Prokopieva

Central City Clinical Hospital No. 6

Email: mbucgkb6@mail.ru
PhD, Deputy Chief physician 620149, Yekaterinburg, 34 S. Deryabinoy Str

Viktor M. Bakhtin

Ural State Medical University of the Ministry of Healthcare of Russia

Email: bakhtin.v95@mail.ru
postgraduate student of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

Anna A. Vikhareva

Ural State Medical University of the Ministry of Healthcare of Russia

Email: anna1993vi@gmail.com
postgraduate student of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

Leonid I. Kadnikov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: kadn-leonid@mail.ru
resident of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

References

  1. Fu L., Wang B., Yuan T. et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and metaanalysis. J Infect. 2020; 80(6): 656-65. doi: 10.1016/j.jinf.2020.03.041.
  2. Xie Y., Wang Z., Liao H. et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020; 20(1): 640. doi: 10.1186/s12879-020-05371-2.
  3. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 7 (03.06.2020). Доступ: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/ original/03062020_%D0%9CR_C0VID-19_v7.pdf (дата обращения - 09.01.2021).
  4. Costa K.V.T.D., Carnauba A.T.L., Rocha K.W. et al. Olfactory and taste disorders in COVID-19: a systematic review. Braz J Otorhinolaryngol. 2020; 86(6): 781-92. doi: 10.1016/j.bjorl.2020.05.008.
  5. Vaira L.A., Salzano G., Fois A.G. et al. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int Forum Allergy. Rhinol. 2020; 10(9): 1103-04. doi: 10.1002/alr.22593.
  6. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281-86. doi: 10.1007/s12098-020-03263-6.
  7. D'Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea during COVID-19 infection: Pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol. 2020; 18(8): 1663-72. doi: 10.1016/j.cgh.2020.04.001.
  8. Grassia R., Testa S., Pan A., Conti C.B. SARS-CoV-2 and gastrointestinal tract: The dark side of the pandemic. Dig Liver Dis. 2020; 52(7): 700-01. doi: 10.1016/j.dld.2020.04.028.
  9. Zhao Q., Fang X., Pang Z. et al. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020; 34(11): 2505-10. doi: 10.1111/jdv.16778.
  10. Matar S., Oules B., Sohier P. et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol. 2020; 34(11): e686-e689. doi: 10.1111/jdv.16775.
  11. Wenzhong L., Hualan L. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020. Available at: https://chemrxiv.org/articles/preprint/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173/9 (date of access - 09.01.2021). doi: 10.26434/ chemrxiv.11938173.v9.
  12. Cavezzi A., Troiani E., Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin. Pract. 2020; 10(2): 1271. doi: 10.4081/cp.2020.1271
  13. Soraya G.V., Ulhaq Z.S. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis. Med Clin (Barc). 2020; 155(4): 143-51. doi: 10.1016/j.medcli.2020.05.017.
  14. Violi F., Pastori D., Cangemi R. et al. Hypercoagulation and antithrombotic treatment in coronavirus 2019: A new challenge. Thromb Haemost. 2020; 120(6): 949-56. doi: 10.1055/s-0040-1710317.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies